| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Equipe de l’Interferon et des Cytokines, Unité Mixte de Recherche 146, Centre National de la Recherche Scientifique Institut Curie, Orsay, France
Constitutive expression of IFN-ß by HIV target cells may be an
alternative or complementary therapeutic approach for the treatment of
AIDS. We show that macrophages derived from CD34+ cells
from umbilical cord blood can be efficiently transduced by a retroviral
vector carrying the IFN-ß coding sequence. This results in resistance
to infection by a macrophage-tropic HIV type 1, as shown by the drastic
reduction in the HIV DNA copy number per cell and in p24 release.
Moreover, IFN-ß transduction totally blocked secretion of
proinflammatory cytokines after HIV infection. The constitutive IFN-ß
production also resulted in an increased production of IL-12 and
IFN-
Th1-type cytokines and of the ß-chemokines
macrophage-inflammatory protein-1
, macrophage-inflammatory
protein-1ß, and RANTES. RANTES was found to be involved in the HIV
resistance observed, and this was correlated with a down-regulation of
the CCR-5 HIV entry coreceptor. These results demonstrate the
feasibility and the efficacy of such IFN-ß-mediated gene therapy. In
addition to inhibiting HIV replication, IFN-ß transduction could have
beneficial immune effects in HIV-infected patients by favoring cellular
immune responses.
This article has been cited by other articles:
|
|
 |
|
  S. W. Cole Psychosocial Influences on HIV-1 Disease Progression: Neural, Endocrine, and Virologic Mechanisms Psychosom Med, June 1, 2008; 70(5): 562 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bourne, F. Scholle, M. C. Silva, S. L. Rossi, N. Dewsbury, B. Judy, J. B. De Aguiar, M. A. Leon, D. M. Estes, R. Fayzulin, et al. Early Production of Type I Interferon during West Nile Virus Infection: Role for Lymphoid Tissues in IRF3-Independent Interferon Production J. Virol., September 1, 2007; 81(17): 9100 - 9108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Audige, E. Schlaepfer, H. Joller, and R. F. Speck Uncoupled Anti-HIV and Immune-Enhancing Effects when Combining IFN-{alpha} and IL-7 J. Immunol., September 15, 2005; 175(6): 3724 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Foster, S. H. Masri, R. David, M. Jones, A. Datta, G. Lombardi, L. Runkell, C. de Dios, I. Sizing, M. J. James, et al. IFN-{alpha} Subtypes Differentially Affect Human T Cell Motility J. Immunol., August 1, 2004; 173(3): 1663 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rogez, M. Martin, N. Dereuddre-Bosquet, J. Martal, D. Dormont, and P. Clayette Anti-Human Immunodeficiency Virus Activity of Tau Interferon in Human Macrophages: Involvement of Cellular Factors and {beta}-Chemokines J. Virol., December 1, 2003; 77(23): 12914 - 12920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Burke, S. Sumner, N. Maitland, and C. E. Lewis Macrophages in gene therapy: cellular delivery vehicles and in vivo targets J. Leukoc. Biol., September 1, 2002; 72(3): 417 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Brassard, M. J. Grace, and R. W. Bordens Interferon-{alpha} as an immunotherapeutic protein J. Leukoc. Biol., April 1, 2002; 71(4): 565 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Matheux, E. Lauret, V. Rousseau, J. Larghero, B. Boson, B. Vaslin, A. Cheret, E. De Maeyer, D. Dormont, and R. LeGrand Simian immunodeficiency virus resistance of macaques infused with interferon {beta}-engineered lymphocytes J. Gen. Virol., November 1, 2000; 81(11): 2741 - 2750. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
